Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Abeona Therapeutics (ABEO) EBITDA Margin: 2011-2025

Historic EBITDA Margin for Abeona Therapeutics (ABEO) over the last 14 years, with Sep 2025 value amounting to -662.26%.

  • Abeona Therapeutics' EBITDA Margin rose 3407223.00% to -662.26% in Q3 2025 from the same period last year, while for Sep 2025 it was 5,789.61%, marking a year-over-year increase of 1550465.00%. This contributed to the annual value of -167,526.32% for FY2024, which is 16597989.00% down from last year.
  • Per Abeona Therapeutics' latest filing, its EBITDA Margin stood at -662.26% for Q3 2025, which was down 102.43% from 27,213.75% recorded in Q2 2025.
  • Abeona Therapeutics' EBITDA Margin's 5-year high stood at 97,293.75% during Q4 2021, with a 5-year trough of -34,734.48% in Q3 2024.
  • Its 3-year average for EBITDA Margin is 2,720.35%, with a median of -662.26% in 2025.
  • As far as peak fluctuations go, Abeona Therapeutics' EBITDA Margin spiked by 9,782,225bps in 2021, and later plummeted by 10,789,081bps in 2022.
  • Abeona Therapeutics' EBITDA Margin (Quarterly) stood at 97,293.75% in 2021, then crashed by 10,789,081bps to -10,597.06% in 2022, then skyrocketed by 798,539bps to -2,611.67% in 2023, then surged by 1,820,659bps to 15,594.92% in 2024, then skyrocketed by 3,407,223bps to -662.26% in 2025.
  • Its EBITDA Margin stands at -662.26% for Q3 2025, versus 27,213.75% for Q2 2025 and -3,879.49% for Q1 2025.